ifosfamide + doxorubicin + gemcitabine + docetaxel

This is a four-drug combination chemotherapy regimen consisting of ifosfamide, doxorubicin, gemcitabine, and docetaxel. Each component is a cytotoxic agent with distinct mechanisms of action: - Ifosfamide is an alkylating agent that crosslinks DNA strands, leading to inhibition of DNA replication and cell death. - Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in DNA damage and apoptosis. - Gemcitabine is a nucleoside analog (antimetabolite) that incorporates into DNA during replication, causing chain termination. - Docetaxel is a taxane that stabilizes microtubules and prevents their depolymerization, thereby inhibiting mitosis. This combination has been explored in the neoadjuvant or adjuvant setting for high-risk soft tissue sarcoma (STS), as well as in other advanced or refractory solid tumors. The rationale for combining these agents lies in their non-overlapping mechanisms of action and toxicity profiles. While combinations such as doxorubicin plus ifosfamide or gemcitabine plus docetaxel are established regimens for STS[1][2][4], sequential use or combinations involving all four drugs have been investigated primarily in clinical trials[7]. Toxicities can be significant due to the cumulative effects on bone marrow suppression and organ function.